Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 5/2024

01-02-2024 | Hepatocellular Carcinoma | ASO Author Reflections

ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?

Authors: Jun-Yi Wu, MD, PhD, Jia-Yi Wu, MD, Yang-Kai Fu, MD, Mao-Lin Yan, MD, PhD

Published in: Annals of Surgical Oncology | Issue 5/2024

Login to get access

Excerpt

Conversion therapy for unresectable hepatocellular carcinoma (uHCC) with transcatheter arterial chemoembolization (TACE), lenvatinib plus anti-PD-1 antibodies (PD-1) (triple therapy) has a high rate of tumor response and shown the potential to achieve long-term survival.1,2 Some studies have reported that salvage surgery (SR) is safe and improve the prognosis of uHCC after conversion therapy.3,4 However, most of these studies tended to be single-arm trials and have small number of cases. The impact of SR in uHCC after conversion therapy remain unknown. Thus, we performed a retrospective analysis to compare the impact of SR and non-SR in uHCC after conversion therapy with triple therapy. …
Literature
1.
Wu JY, Yin ZY, Bai YN, et al. Lenvatinib combined with anti-PD-1 antibodies plus transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma: a multicenter retrospective study. J Hepatocellular Carcinoma. 2021;8:1233–40.CrossRef
2.
Li X, Chen J, Wang X, et al. Outcomes and prognostic factors in initially unresectable hepatocellular carcinoma treated using conversion therapy with lenvatinib and TACE plus PD-1 inhibitors. Front Oncol. 2023;13:1110689.CrossRefPubMedPubMedCentral
3.
Wu JY, Zhang ZB, Zhou JY, et al. Outcomes of salvage surgery for initially unresectable hepatocellular carcinoma converted by transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibodies: a multicenter retrospective study. Liver Cancer. 2023;12:229–37.CrossRefPubMed
4.
Zhu XD, Huang C, Shen YH, et al. Hepatectomy after conversion therapy using tyrosine kinase inhibitors plus anti-pd-1 antibody therapy for patients with unresectable hepatocellular carcinoma. Ann Surg Oncol. 2023;30:2782–90.CrossRefPubMed
5.
Wu JY, Wu JY, Fu YK, et al. Outcomes of salvage surgery versus non-salvage surgery for initially unresectable hepatocellular carcinoma after conversion therapy with transcatheter arterial chemoembolization combined with lenvatinib plus anti-PD-1 antibody: a multicenter retrospective study. Ann Surg Oncol. 2024. https://​doi.​org/​10.​1245/​s10434-024-14944-3.CrossRefPubMed
Metadata
Title
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
Authors
Jun-Yi Wu, MD, PhD
Jia-Yi Wu, MD
Yang-Kai Fu, MD
Mao-Lin Yan, MD, PhD
Publication date
01-02-2024
Publisher
Springer International Publishing
Published in
Annals of Surgical Oncology / Issue 5/2024
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-024-14991-w

Other articles of this Issue 5/2024

Annals of Surgical Oncology 5/2024 Go to the issue

ASO Author Reflections

ASO Author Reflections: Laparoscopic Surgery for Intrahepatic Cholangiocarcinoma—Opportunities and Challenges

ASO Visual Abstract

ASO Visual Abstract: Preoperative Frailty and Malnutrition in Surgical Oncology Patients Predicts Higher Postoperative Adverse Events and Worse Survival—Results of a Blinded, Prospective Trial

Urologic Oncology

Gross Hematuria Does not Affect the Selection of Nephrectomy Types for Clinical Stage 1 Clear Cell Renal Cell Carcinoma: A Multicenter, Retrospective Cohort Study

Thoracic Oncology

Comment on “Neoadjuvant Chemotherapy or Neoadjuvant Chemoradiotherapy for Patients with Esophageal Squamous Cell Carcinoma: Real-World Data Comparison from a Japanese Nationwide Study”

Pancreatic Tumors

Pancreatic Neuroendocrine Tumors and Lymph Nodes: How Much Surgery is Enough?

Hepatobiliary Tumors

Use of a Perfused Cadaver for Training of Robotic Pancreaticoduodenectomy Allows for Realistic Tissue Dissection and Management of Intra-Operative Bleeding